Examining the different immunotherapy treatments present in our patient cohort, we were able to attribute the lymphedema protective effect to the anti-CTLA4 monotherapy, which reduced lymphedema risk to the level of the lymph node biopsy risk group. The gene discussed is CTLA4; the disease is lymphedema.